SECOND AMENDMENT TO THE LICENSE AGREEMENTLicense Agreement • March 11th, 2024 • Lirum Therapeutics, Inc. • Pharmaceutical preparations
Contract Type FiledMarch 11th, 2024 Company IndustryThis Second Amendment to the License Agreement (this “Second Amendment”) is made and entered into this 11th day of July 2023, by and among IGF Oncology, LLC, a Delaware limited liability company (“IGF”), and Lirum Therapeutics, Inc., a Delaware corporation (“LIRUM”). IGF and LIRUM are from time to time referred to herein individually as a “Party” or collectively as the “Parties”.
SECOND AMENDMENT TO THE LICENSE AGREEMENTLicense Agreement • February 2nd, 2024 • Lirum Therapeutics, Inc. • Pharmaceutical preparations
Contract Type FiledFebruary 2nd, 2024 Company IndustryThis Second Amendment to the License Agreement (this “Second Amendment”) is made and entered into this [11th] day of July 2023, by and among IGF Oncology, LLC, a Delaware limited liability company (“IGF”), and Lirum Therapeutics, Inc., a Delaware corporation (“LIRUM”). IGF and LIRUM are from time to time referred to herein individually as a “Party” or collectively as the “Parties”.